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Abstract 
The increase of elderly population in Indonesia leads to the drug misuse. The physiological change in 
geriatric become the major reason. It affects the change of    drug’s pharmacodynamic, 
pharmacokinetics and the harmful drug interaction among overly prescribed medication. 
Cardiovascular drugs produce the most common side effect in elderly patient. This study aims to 
observe the accuracy of cardiovascular drugs used based on its dose and drug interaction. The 
subject of this study are the 60 years old-or more- inpatients in Rumah Sakit Umum Zainoel Abidin’s 
(RSUDZA) Internal medicine ward who received cardiovascular drugs prescription. The data were 
collected from medical record and nurse’s drugs record. The analysis were performed descriptively by 
evaluate the drug interaction theoritically based on literature study and available concensuses. The 
result shows that the Potential interaction occurred  in 75 ( 68.18 % ) of cardiovascular drug used, 
and 22 (20 %) of whom are important potential interactions. The most frequent drugs that have the 
potential interaction in this study are furosemide , spironolactone, captopril, digoxin and aspirin. 
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Introduction 
Drug prescribtion in elderly becomes crucial due to their age-related  physical change such reduction 
of weight, albumin and body fluid, the increase of  body fat, and  alleviation of organ function. Those 
physical change affects the pharmacodynamics and pharmacocinetics of the drugs and indirectly affect 
the drug doses.  This condition leads to a misuse of drugs in elderly (Aronow, 2007, Finestone et al., 
2007). Epidemiological study shows that elderly patients are on the high risk of drug’s side effect. 
Drug’s side effect in 70-79 years old patient is seven times higher compared to 20-29 years old 
patient (Laroche et al, 2006). This incidence occurs due to polypharmacy practice among elderly. 
Polypharmacy is defined by the use of multiple drugs (more than 5 type of drugs)  in one periode of 
time. Several diseases that are commonly found in elderly patients causes the polypharmacy practice 
which is hard to be avoided. Some studies showed a positive correlation between the number of drugs 
that had been taken and  the high risk of side effect and drug interaction. In elderly patients who 
consume 10 type of drugs, the risk of  drug’s side effect is more than 50% (Raza and Moyahed, 2002, 
Routledge et al, 2003). Cardiovascular drugs are the most common drugs that can cause side effect 
(Laroche et al., 2006). 
 
A survey in Indonesia showed 78%  of elderly suffered 4 diseases at the same time, 38% elderly live 
with 6 diseases and 13 % have 8 diseases (Rahmawati et al., 2009). Another study in Sardjito 
Hospital in Jogjakarta (Rahmawati F et al., 2006) stated that the highest risk drug interaction occurred 
in cardiovascular drugs.  Approximately 59%  elderly patients in hospital ward experienced the drug 
interaction from Furosemid, Captopril and Aspirin.  The use of cardiovascular drugs in Aceh is still not 
well-recorded. Therefore, our goal is to observe the accuracy of cardiovascular drugs prescription 
among elderly patients based on its interaction potency. 
 
Materials and Methods 
This study is a descriptive study with cross-sectional design. The data were collected retrospectively 
from 50 medical records of the 60 years old-or more- patients in RSUDZA’s internal medicine ward. 
The  interval of data collection ranged  from January 2014 to march 2014. The main data that were 
recorded are the identity (name, age, gender, weight, hospital admission date, out of treatment date, 
medical record’s number), problems, diagnose, therapy (including dose, frequency, drug 
administrastion, duration of drug prescription, number of drugs that given), and   additional 
examination.  We compare the therapeutic data from medical records with the nurse record.  In case 
it is not in accordance with each other,  the nurse’s record will be taken as the primary data. 
 
The data were collected subsequently in a table and analyzed descriptively. The accurracy of drug 
administration was evaluated based on reference and recommendation from concensus and literature. 
Those concensus and litetature are: Pedoman Tata Laksana Penyakit Kardiovaskular di Indonesia/ 
Guidance   of   cardiovascular   Treatment   in   Indonesia   (2009),   Goodman   and   Gilman’s   The 
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Pharmacological Basis of Therapeutic edisi 11 (2006), Martindale the Complete Drug Reference edisi 
34 (2005), Drugs for the Heart edisi 6 (2005), dan Geriatric Dosage Handbook edisi 6 (2001). 
 
Results and Discussion 
This study was attended by 50 cardiovascular-drugs using patients. Among those number, 54% are 
male and 80 % are in between 60-74 years old (Table 1). 
 
Tabel  1. Characteristic of  Hospitalized Geriatric Patients    
   Variables                   Number of patients                     %   
Gender 
Male                                                      27                                  54 
  Female                                                  23                                  46   
 
Age Group (years)  
60-74 40  80 
75-90 10  20 
  > 90                                                       0                                    0   
 
The Number of  
medication prescribed 
< 5 
 
11 
  
22 
5 – 9 29  58 
> 10                                                     10                                  20   
 
Total                                                     50                                 100 
 
The total  344 drugs were used in all patients. In between, 110 drugs are cardiovascular drugs (Table 
2). The range of used drugs per patient were 2-13 drugs. Most of them consumed 7 drugs. 
 
Table 2. the percentage of cardiovascular drugs     
 
       Type of cardiovascular drugs             n       Number of use Percentage (%)   
 
 
Diuretic 
 
24  
 
21,82 
Furosemid 14  12,73 
Spironolacton 6  5,45 
Hidroclorotiazid 4  3,64 
ACE inhibitor 9  8,18 
Captopril 6  5,45 
Ramipril 2  1,82 
Imidapril 1  0,91 
Angiotensin Receptor Inhibitor 24  21,82 
Valsartan 10  9,09 
Candesartan 13  11,82 
Telmisartan 1  0,91 
Calcium Channel Blocker 29  26,36 
Amlodipin 29  26,36 
Beta blocker 3  2,72 
Bisoprolol 3  2,73 
Heart Glikoside 3  2,72 
Digoksin 3  2,73 
Antiplatelet 14  12,73 
Aspirin 10  9,09 
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Klopidogrel 
 
4 
 
3,64 
Anticoagulan 4 3,64 
Warfarin 2 1,82 
Na enoksaparin 2 1,82 
Total 110 100 
 
Amongst 110 cardiovascular drugs, there are 75 (68,18%) drugs which have interaction potency and 
22 (20%) drugs which have to be restrictively supervised (Table 3). The type of drugs with potency of 
interaction are similar to other researches before such as furosemid, spironolacton, captopril, digoxin 
and aspirin. A study from Sardjito Hospital in Jogjakarta stated that there were 48 incidences of drugs 
interaction from  90 elderly patients in the ward. Among that number, 36 (75%) incidences involved 
cardiovascular  drugs.  The  most  common  interaction  of cardiovascular  drugs  in that  study  were 
furosemid, captoril, and aspirin (Rachmawati, 2006). Other study from Cipto Mangun Kusumo Hospital 
(RSCM) mentioned that in between 347 drugs (104 among them were cardiovascular drugs), 25 drugs 
(7,2%)  had  interaction  potency  and  18  drugs  (72%)  involved  cardiovascular  drugs.  The  most 
prominent interaction of cardiovascular drugs in this study come from captopril, furosemid, aspirin, 
and enoksaparin (Suardi, 2010). The high used of cardiovascular drugs that have interaction potency 
in those two researches indicate that the choice for cardiovascular drugs should be thoughtful and 
accurate in order to minimize the drug interaction. Drug interaction increases depend on age and the 
number of prescribed drugs (Midlov, 2009). This increase jumps exponentially. The interaction risk to 
the   patient who consume   2 type of drugs is 6% but the risk jumps into 50 % in patients who 
consume 5 type of drugs and 100 % to the patient that consume 10 type of drugs (Lin, 2003). 
 
In  2004,    the  American  Medical  Directors  Association  and  the  American  Society  of  Consultant 
Pharmacist established a committee which was called by Multidisciplinary Medication Management 
Project. This committee aims to identify 10 type of the most cautious drugs among all drugs that used 
to be long-term prescribed to the elderly patient. Those drugs are warfarin–NSAID, warfarin–sulfa 
type antibiotics, warfarin–macrolid antibiotics, warfarin–cuinolon, warfarin–fenitoin, ACEi–Kalium, 
ACEi–spironolacton, digoxin–amiodaron, digoxin–verapamil, and teofilin–kuinolon (Brown, 2010).  In 
brief, the cardiovascular drugs that have crucial interaction are warfarin, ACE inhibitor, spironolacton, 
digoxin, amiodaron and verapamil. 
 
Table  3. The drugs with their potential drug interaction 
 
  No            Drug I                    Drug 2                       Mechanism of Interaction              Number of use   
 
 
1 
 
Furosemid  
 
Aspirin  
 
reduce diuretic’s efication  
 
4 
2 Spironolacton  Captopril  elevate the risk of hipercalemia  2 
3 Spironolacton  KSR  elevate the risk of hipercalemia  1 
4 Spironolacton  Ramipril  elevate the risk of hipercalemia  1 
5 Spironolacton  Imidapril  elevate the risk of hipercalemia  1 
6 Captopril  Aspirin  reduce antihipertensi response  2 
7 Captopril  Aspar K  reduce captopril absorbtion  1 
8 Captopril  KSR  elevate the risk of hipercalemia  2 
9 Ramipril  Aspirin  reduce antihipertensi response  1 
10 Digoxin  Furosemid  elevate digoxin toxicity by hipocalemia  1 
11 Digoxin  Bisoprolol  elevate inhibition of AV  1 
12 Warfarin  Levofloxacin  elevate effect of warfarin anticoagulan  1 
13 Clopidogrel  Omeprazol  reduce anticoagulan effect  1 
14 Clopidogrel  Aspirin  elevate the risk of bleeding  2 
15 Aspirin  Na enoksaparin  elevate the risk of bleeding  1 
 Total      22 
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Warfarin oral anticoagulan has the possibility to develop Adverse Drug Reaction (ADR) due to the high 
drug interaction. Those risk are triggered by the narrow theurapetic index of Warfarin. In addition, 
warfarin’s dose also needs to be individualized.  Any change in other drug’s dose can influence patient 
respons to warfarin. Severe bleeding often occur in 1-5 % cases per year with 25-30 mortality cases. 
(Ho LL et al., 2002). This study exposed that the use of Warfarin was decline in the elderly. From 110 
cardiovascular drug’s user, only 2 patients used Warfarin. These two patient also shown the potency 
of  interaction to other drugs that they consumed. Digoxin also has a high potency of interaction. In 
our study, there were 3 patients with digoxin treatment. Digoxin are known for its narrow therapeutic 
index.  Digoxin’s plasma concentration is not respectively described its effects and activities. Digoxin 
are recommended  for small amount use with restrictive control due to its toxicity (Raza and Movahed, 
2002). Patient with renal function alleviation  are recommended  to take  a daily dose of  0.125 mg or 
interval one day dose of 0.125 mg digoxin (Ahmed, 2007). 
 
Other drugs with the high risk of interaction are ACE inhibitor and Spironolacton. There are several 
conditions that can cause severe hiperkalemia  in a heart failure patient with spironolacton,  ACE 
inhibitor or AT1 Receptor Blocker (ARB)  therapy. Those are elderly patient, consume more than 25 
mg of spironolacton daily, alleviation of renal function and Diabetes mellitus type 2.  Kalium’s plasma 
concentration should be monitored periodically in these patients.   Experts suggested to restrict the 
use of spironolacton  to less than 25 mg a day or with the one day interval (Wrenger et al., 2003) 
 
Most of drug interaction could be predicted, avoided and minimized by a proper education about 
pharmacodynamic  and pharmacokinetics.   Therefore, the prescription of important cardiovascular 
drugs should not be stopped solely because of its potency of interaction. Alternative steps can  be 
performed to handle the drug interaction effectively  such as dose attenuation,  high risk patient 
supervision,   or treatment continuation if the drug effect is already in optimal dose or no clinically 
relevant interaction (Lin P, 2003, Hines L, 2008) 
 
Conclusion 
Incidence of cardiovascular drug interaction in hospitalized geriatric patients in RSUDZA Banda Aceh 
was substantial. The Potential interaction occurred  in 75 ( 68.18 % ) of cardiovascular drug used, and 
22 (20%) drugs which have to be restrictively supervised. The most frequent drugs that have the 
potential interaction in this study are furosemide, spironolactone , captopril ,digoxin and aspirin. 
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